Jeffrey Grass, MD
Radiation Oncology · Fairfield, OHNPI 1275574535
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $3,866 of the $5,199 with a category attached, or 74.4%. 22 manufacturers reported payments, led by Siemens Medical Solutions USA, Inc. at 31.2% of the total. Reporting peaked in 2024 at $2,582 and has fallen 70.7% since, to $757 in 2025.
Across 93 payments — averaging $55.90 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Siemens Medical Solutions USA, Inc.$2K
- Janssen Scientific Affairs, LLC$674
- Bayer$435
- Dendreon Pharmaceuticals LLC$357
- Novartis$248
- Boston Scientific$237
- plus $2K from 16 others
What the payments were for
- Travel & lodging$1,33326%
- Food & beverage$3,86674%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Siemens Medical Solutions USA, Inc. | 5 | $1,619 |
| Janssen Scientific Affairs, LLC | 5 | $674 |
| Bayer | 12 | $435 |
| Dendreon Pharmaceuticals LLC | 11 | $357 |
| Novartis | 12 | $248 |
| Boston Scientific | 5 | $237 |
| Progenics Pharmaceuticals, Inc. | 6 | $219 |
| Teleflex LLC | 4 | $216 |
| Johnson & Johnson | 12 | $202 |
| Myovant Sciences Inc. | 2 | $150 |
| Elekta, Inc. | 1 | $125 |
| AstraZeneca | 1 | $120 |
| Bioprotect Medical, Inc. | 1 | $117 |
| Myriad Genetic Laboratories, Inc. | 1 | $109 |
| Ferring Pharmaceuticals Inc. | 2 | $91 |
| Sumitomo Pharma America, Inc. | 5 | $85 |
| Immunitybio, Inc. | 1 | $67 |
| Pfizer | 2 | $31 |
| Astellas Pharma US Inc | 2 | $30 |
| Merck | 1 | $27 |
| Bard Peripheral Vascular, Inc. | 1 | $20 |
| Urogen Pharma, Inc. | 1 | $19 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Erleada$674
- Varian Ethos Treatment Planning$386
- Xofigo$271
- Nubeqa$271
- TrueBeam$159
- PROVENGE$150
- AKEEGA$147
- Balversa$142
- ELEKTA MEDICAL LINEAR ACCELERATOR$125
- THERASPHERE$125
- Pipeline$124
- PYLARIFY$121
- ORGOVYX$121
- LYNPARZA$120
- BIOPROTECT BALLOON IMPLANT SYSTEM$117
- Prolaris$109
How this compares
$5,199 in reported general payments places this provider in the 85th percentile of 255 radiation oncology providers in Ohio.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Tamsulosin Hcl | 108 | $954 |
| Dexamethasone | 20 | $227 |
Paid to pharmacies, not to this prescriber.
Other radiation oncology in Fairfield
- Peter FriedFairfield$45K
- Steven KurtzmanGarfield Heights$833K
- Joshua PalmerColumbus$123K
- Norleena PoynterSandusky$90K
- Daniel SprattCleveland$86K
- Shlomo KoyfmanCleveland$72K
- Gerald SokolCleveland$61K
- Rahul TendulkarCleveland$26K
- Sujith BaligaColumbus$26K
- Anthony ParavatiKettering$24K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.